. 2020 Apr; 12(4):.
doi: 10.3390/cancers12040821.

Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine

Christopher Montemagno 1 Gilles Pagès 1 
  • PMID: 32235331
  •     100 References
  •     2 citations


Breast cancer is the most common malignancy in women throughout the world. Metastatic dissemination to vital organs is the leading cause of breast cancer-related deaths. The treatment of metastases is mainly based on the primary tumor characteristics. However, breast cancer metastases exhibit high heterogeneity leading to different prognosis and therapeutic responses. Getting access to phenotype of metastases would allow better management of patients. The advent of theranostics in nuclear medicine has opened new opportunities for the diagnosis and treatment of cancer patients. The aim of this review is to provide an overview of current knowledge and future directions in nuclear medicine for therapeutic management of metastatic breast cancer patients.

Keywords: breast cancer; metastasis; nuclear medicine; theranostics.

Hematogenous and lymphatic tumor cell dissemination may be detected in patients diagnosed with ductal carcinoma in situ of the breast.
Malgorzata Banys, Ines Gruber, +8 authors, Tanja Fehm.
Breast Cancer Res Treat, 2011 Apr 02; 131(3). PMID: 21455667
On the origin of cancer metastasis.
Thomas N Seyfried, Leanne C Huysentruyt.
Crit Rev Oncog, 2012 Dec 15; 18(1-2). PMID: 23237552    Free PMC article.
Highly Cited. Review.
Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ.
Nicole Sänger, Katharina E Effenberger, +6 authors, Klaus Pantel.
Int J Cancer, 2011 Jan 06; 129(10). PMID: 21207426
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Michael S Hofman, John Violet, +12 authors, Shahneen Sandhu.
Lancet Oncol, 2018 May 13; 19(6). PMID: 29752180
Highly Cited.
Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
Yee-Lu Tham, Krystal Sexton, +2 authors, Richard Elledge.
Cancer, 2006 Jul 11; 107(4). PMID: 16826579
Models, mechanisms and clinical evidence for cancer dormancy.
Julio A Aguirre-Ghiso.
Nat Rev Cancer, 2007 Oct 25; 7(11). PMID: 17957189    Free PMC article.
Highly Cited. Review.
Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT.
Gary A Ulaner, David M Hyman, +10 authors, Jorge A Carrasquillo.
J Nucl Med, 2016 May 07; 57(10). PMID: 27151988    Free PMC article.
Highly Cited.
New insights on cell death from radiation exposure.
Kevin M Prise, Giuseppe Schettino, Melvyn Folkard, Kathryn D Held.
Lancet Oncol, 2005 Jul 05; 6(7). PMID: 15992701
Adaptive immunity maintains occult cancer in an equilibrium state.
Catherine M Koebel, William Vermi, +5 authors, Robert D Schreiber.
Nature, 2007 Nov 21; 450(7171). PMID: 18026089
Highly Cited.
Theranostics in nuclear medicine practice.
Anna Yordanova, Elisabeth Eppard, +6 authors, Markus Essler.
Onco Targets Ther, 2017 Oct 19; 10. PMID: 29042793    Free PMC article.
Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.
Eva J ter Weele, Anton G T Terwisscha van Scheltinga, +6 authors, Elisabeth G E de Vries.
Oncotarget, 2015 Nov 05; 6(39). PMID: 26536664    Free PMC article.
68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology.
Simone U Dalm, Ingrid L Bakker, +8 authors, Marion de Jong.
J Nucl Med, 2016 Sep 10; 58(2). PMID: 27609789
Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
Linda Sofie Lindström, Eva Karlsson, +6 authors, Jonas Bergh.
J Clin Oncol, 2012 Jun 20; 30(21). PMID: 22711854
Highly Cited.
Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials.
Ronald L Van Heertum, Robert Scarimbolo, +2 authors, Michael O'Neal.
Drug Des Devel Ther, 2015 Sep 24; 9. PMID: 26392755    Free PMC article.
68Ga/177Lu-labeled DOTA-TATE shows similar imaging and biodistribution in neuroendocrine tumor model.
Fei Liu, Hua Zhu, +6 authors, Zhi Yang.
Tumour Biol, 2017 Jun 18; 39(6). PMID: 28618966
HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy.
Alfredo Santinelli, Eleonora Pisa, Daniela Stramazzotti, Guidalberto Fabris.
Int J Cancer, 2007 Nov 02; 122(5). PMID: 17973263
Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.
S Braun, K Pantel, +9 authors, G Schlimok.
N Engl J Med, 2000 Feb 24; 342(8). PMID: 10684910
Highly Cited.
Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
Catarina Xavier, Ilse Vaneycken, +7 authors, Vicky Caveliers.
J Nucl Med, 2013 Mar 15; 54(5). PMID: 23487015
Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry.
Levent Kabasakal, Türkay Toklu, +7 authors, Nalan Alan Selçuk.
Mol Imaging Radionucl Ther, 2017 Jun 15; 26(2). PMID: 28613198    Free PMC article.
Repeated observation of breast tumor subtypes in independent gene expression data sets.
Therese Sorlie, Robert Tibshirani, +13 authors, David Botstein.
Proc Natl Acad Sci U S A, 2003 Jun 28; 100(14). PMID: 12829800    Free PMC article.
Highly Cited.
Estrogen receptor levels in multiple biopsies from patients with breast cancer.
D J Webster, D G Bronn, J P Minton.
Am J Surg, 1978 Sep 01; 136(3). PMID: 707701
Variation in receptor status between primary and metastatic breast cancer.
I M Holdaway, J V Bowditch.
Cancer, 1983 Aug 01; 52(3). PMID: 6861087
Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study.
Qi Wu, Juanjuan Li, +6 authors, Shengrong Sun.
Oncotarget, 2017 Apr 22; 8(17). PMID: 28427196    Free PMC article.
Highly Cited.
Cancer micrometastasis and tumour dormancy.
Harriet Wikman, Robert Vessella, Klaus Pantel.
APMIS, 2008 Oct 07; 116(7-8). PMID: 18834417
Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells.
Nicole Grabinski, Kai Bartkowiak, +3 authors, Manfred Jücker.
Cell Signal, 2011 Jul 23; 23(12). PMID: 21777670
Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
Raffit Hassan, Anish Thomas, +3 authors, Ira Pastan.
J Clin Oncol, 2016 Nov 20; 34(34). PMID: 27863199    Free PMC article.
Highly Cited. Review.
PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma.
Tibor Vag, Katja Steiger, +7 authors, Markus Schwaiger.
EJNMMI Res, 2018 Sep 08; 8(1). PMID: 30191351    Free PMC article.
Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States.
Angela B Mariotto, Ruth Etzioni, +2 authors, Musa Mayer.
Cancer Epidemiol Biomarkers Prev, 2017 May 20; 26(6). PMID: 28522448    Free PMC article.
Highly Cited.
Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14).
Jean Claude Reubi, Sandra Wenger, +2 authors, Mathias Gugger.
Clin Cancer Res, 2002 Apr 12; 8(4). PMID: 11948125
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management.
Valentina Guarneri, Simona Giovannelli, +8 authors, PierFranco Conte.
Oncologist, 2008 Jul 25; 13(8). PMID: 18650259
Subtypes of breast cancer show preferential site of relapse.
Marcel Smid, Yixin Wang, +5 authors, John W M Martens.
Cancer Res, 2008 May 03; 68(9). PMID: 18451135
Highly Cited.
Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization.
Patrick Maier, Linda Hartmann, Frederik Wenz, Carsten Herskind.
Int J Mol Sci, 2016 Jan 20; 17(1). PMID: 26784176    Free PMC article.
Highly Cited. Review.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer.
Ilse Vaneycken, Nick Devoogdt, +6 authors, Vicky Caveliers.
FASEB J, 2011 Apr 12; 25(7). PMID: 21478264
Molecular portraits of human breast tumours.
C M Perou, T Sørlie, +15 authors, D Botstein.
Nature, 2000 Aug 30; 406(6797). PMID: 10963602
Highly Cited.
Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer.
Christoph A Klein, Thomas J F Blankenstein, +4 authors, Gert Riethmüller.
Lancet, 2002 Sep 21; 360(9334). PMID: 12241875
Highly Cited.
Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
Matthias D'Huyvetter, Cécile Vincke, +8 authors, Tony Lahoutte.
Theranostics, 2014 Jun 03; 4(7). PMID: 24883121    Free PMC article.
64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer.
Kenji Tamura, Hiroaki Kurihara, +17 authors, Yasuhiro Fujiwara.
J Nucl Med, 2013 Sep 14; 54(11). PMID: 24029656
Highly Cited.
A novel PET imaging using ⁶⁴Cu-labeled monoclonal antibody against mesothelin commonly expressed on cancer cells.
Kazuko Kobayashi, Takanori Sasaki, +7 authors, Eiji Matsuura.
J Immunol Res, 2015 Apr 18; 2015. PMID: 25883990    Free PMC article.
Systemic spread is an early step in breast cancer.
Yves Hüsemann, Jochen B Geigl, +8 authors, Christoph A Klein.
Cancer Cell, 2008 Jan 03; 13(1). PMID: 18167340
Highly Cited.
Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy.
Shany Koren, Mohamed Bentires-Alj.
Mol Cell, 2015 Nov 23; 60(4). PMID: 26590713
Highly Cited. Review.
Targeting Breast Cancer Metastasis.
Xin Jin, Ping Mu.
Breast Cancer (Auckl), 2015 Sep 19; 9(Suppl 1). PMID: 26380552    Free PMC article.
Molecular mechanisms underlying tumor dormancy.
Nava Almog.
Cancer Lett, 2010 Apr 07; 294(2). PMID: 20363069
Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma.
Jo Eyles, Anne-Laure Puaux, +12 authors, Jean-Pierre Abastado.
J Clin Invest, 2010 May 27; 120(6). PMID: 20501944    Free PMC article.
Highly Cited.
Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy.
Katrijn Broos, Quentin Lecocq, +3 authors, Karine Breckpot.
Theranostics, 2018 Jul 22; 8(13). PMID: 30026866    Free PMC article.
Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study.
Marissa C van Maaren, Linda de Munck, +5 authors, Sabine Siesling.
Int J Cancer, 2018 Oct 29; 144(2). PMID: 30368776
[Intratumor heterogeneity, a Darwinian stumbling block towards personalized medicine?].
Marc Billaud.
Med Sci (Paris), 2013 Jan 08; 28(12). PMID: 23290413
When to order a biopsy to characterise a metastatic relapse in breast cancer.
T Foukakis, G Åström, +2 authors, J Bergh.
Ann Oncol, 2012 Sep 26; 23 Suppl 10. PMID: 22987990
Prognostic factors in 1,038 women with metastatic breast cancer.
R Largillier, J-M Ferrero, +12 authors, E Chamorey.
Ann Oncol, 2008 Jul 22; 19(12). PMID: 18641006    Free PMC article.
Death by protein damage in irradiated cells.
Michael J Daly.
DNA Repair (Amst), 2011 Nov 25; 11(1). PMID: 22112864
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding.
Clemens Kratochwil, Frank Bruchertseifer, +6 authors, Alfred Morgenstern.
J Nucl Med, 2017 Apr 15; 58(10). PMID: 28408529
Highly Cited.
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.
Mike Sathekge, Frank Bruchertseifer, +8 authors, Alfred Morgenstern.
Eur J Nucl Med Mol Imaging, 2018 Sep 21; 46(1). PMID: 30232539    Free PMC article.
Highly Cited.
SEOM clinical guidelines in metastatic breast cancer 2015.
J Gavilá, S Lopez-Tarruella, +7 authors, M Martin.
Clin Transl Oncol, 2015 Dec 20; 17(12). PMID: 26683474    Free PMC article.
[(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer.
Christine E Edmonds, Mehran Makvandi, +8 authors, Robert H Mach.
Am J Nucl Med Mol Imaging, 2016 Apr 14; 6(1). PMID: 27069769    Free PMC article.
What is the Role of the Bystander Response in Radionuclide Therapies?
Darren Brady, Joe M O'Sullivan, Kevin M Prise.
Front Oncol, 2013 Aug 24; 3. PMID: 23967404    Free PMC article.
Tumor cell dormancy.
Roger R Gomis, Sylwia Gawrzak.
Mol Oncol, 2016 Dec 27; 11(1). PMID: 28017284    Free PMC article.
The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.
R G Koleva-Kolarova, M J W Greuter, +8 authors, G H de Bock.
Br J Cancer, 2015 Apr 17; 112(10). PMID: 25880006    Free PMC article.
Receptor expression discrepancy between primary and metastatic breast cancer lesions.
Düriye S Karagöz Özen, Mehmet A Ozturk, +3 authors, Mustafa Özgüroglu.
Oncol Res Treat, 2014 Nov 28; 37(11). PMID: 25427579
Tumour heterogeneity and resistance to cancer therapies.
Ibiayi Dagogo-Jack, Alice T Shaw.
Nat Rev Clin Oncol, 2017 Nov 09; 15(2). PMID: 29115304
Highly Cited. Review.
Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.
Carey K Anders, Lisa A Carey.
Clin Breast Cancer, 2009 Jul 15; 9 Suppl 2. PMID: 19596646    Free PMC article.
Highly Cited. Review.
Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis.
Peter Vaupel.
Oncologist, 2008 Jul 01; 13 Suppl 3. PMID: 18458121
Highly Cited. Review.
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.
Jens Sörensen, Irina Velikyan, +9 authors, Henrik Lindman.
Theranostics, 2016 Feb 16; 6(2). PMID: 26877784    Free PMC article.
Highly Cited.
Synthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography.
Dong Zhou, Wenhua Chu, +5 authors, Robert H Mach.
Bioorg Med Chem, 2014 Feb 08; 22(5). PMID: 24503274    Free PMC article.
Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials.
Loredana Marcu, Eva Bezak, Barry J Allen.
Crit Rev Oncol Hematol, 2018 Feb 28; 123. PMID: 29482781
A nuclear chocolate box: the periodic table of nuclear medicine.
Philip J Blower.
Dalton Trans, 2014 Nov 20; 44(11). PMID: 25406520    Free PMC article.
Review on EGFR Inhibitors: Critical Updates.
Davinder Singh, Bhupinder Kumar Attri, Rupinder Kaur Gill, Jitender Bariwal.
Mini Rev Med Chem, 2016 Mar 22; 16(14). PMID: 26996617
Impact of 68Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis.
Sangwon Han, Sungmin Woo, Yeon Joo Kim, Chong Hyun Suh.
Eur Urol, 2018 Apr 22; 74(2). PMID: 29678358
Highly Cited. Systematic Review.
Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma.
A H McGuire, F Dehdashti, +6 authors, M J Welch.
J Nucl Med, 1991 Aug 01; 32(8). PMID: 1869973
Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis.
Kambiz Rahbar, Matthias Schmidt, +5 authors, Hojjat Ahmadzadehfar.
J Nucl Med, 2016 Apr 09; 57(9). PMID: 27056618
Highly Cited.
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
Jonathan Strosberg, Ghassan El-Haddad, +33 authors, NETTER-1 Trial Investigators.
N Engl J Med, 2017 Jan 12; 376(2). PMID: 28076709    Free PMC article.
Highly Cited.
Diagnostic accuracy and safety of 16α-[18F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study.
Sun Young Chae, Sei Hyun Ahn, +19 authors, Dae Hyuk Moon.
Lancet Oncol, 2019 Mar 09; 20(4). PMID: 30846327
From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression.
Oleg Schmidt-Kittler, Thomas Ragg, +13 authors, Christoph A Klein.
Proc Natl Acad Sci U S A, 2003 Jun 17; 100(13). PMID: 12808139    Free PMC article.
Highly Cited.
Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer.
Xuan Jiang, Weihua Li, +2 authors, Zhenyu Zhang.
Cancer Manag Res, 2019 Jun 14; 11. PMID: 31191001    Free PMC article.
Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer.
Yu-Feng Yang, Ying-Yang Liao, +3 authors, Ning-Fu Peng.
Pathol Res Pract, 2013 Nov 05; 209(12). PMID: 24183366
Discovery of mesothelin and exploiting it as a target for immunotherapy.
Ira Pastan, Raffit Hassan.
Cancer Res, 2014 May 16; 74(11). PMID: 24824231    Free PMC article.
Highly Cited. Review.
Breast cancer brain metastases: biology and new clinical perspectives.
Isabell Witzel, Leticia Oliveira-Ferrer, +2 authors, Harriet Wikman.
Breast Cancer Res, 2016 Jan 20; 18(1). PMID: 26781299    Free PMC article.
Highly Cited. Review.
Preclinical Evaluation of Mesothelin-Specific Ligands for SPECT Imaging of Triple-Negative Breast Cancer.
Christopher Montemagno, Sandrine Bacot, +9 authors, Catherine Ghezzi.
J Nucl Med, 2018 Mar 25; 59(7). PMID: 29572256
Estrogen receptor protein (ERP) in multiple tumor specimens from individual patients with breast cancer.
P P Rosen, C J Menendez-Botet, +2 authors, M K Schwartz.
Cancer, 1977 May 01; 39(5). PMID: 870169
Tumoral heterogeneity of breast cancer.
Aurélie Roulot, Delphine Héquet, +4 authors, Roman Rouzier.
Ann Biol Clin (Paris), 2016 Nov 17; 74(6). PMID: 27848916
Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival.
Ahmedin Jemal, Elizabeth M Ward, +13 authors, Hannah K Weir.
J Natl Cancer Inst, 2017 Apr 05; 109(9). PMID: 28376154    Free PMC article.
Highly Cited.
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control.
Clemens Kratochwil, Frank Bruchertseifer, +4 authors, Alfred Morgenstern.
J Nucl Med, 2018 Jan 13; 59(5). PMID: 29326358
Highly Cited.
Biopsy of liver metastasis for women with breast cancer: impact on survival.
Edoardo Botteri, Davide Disalvatore, +6 authors, Nicole Rotmensz.
Breast, 2012 Jan 04; 21(3). PMID: 22212746
18F-Fluoroestradiol Positron Emission Tomography in Breast Cancer Patients: Systematic Review of the Literature & Meta-Analysis.
Laura Evangelista, Valentina Guarneri, Pier Franco Conte.
Curr Radiopharm, 2016 Oct 25; 9(3). PMID: 27774910
Systematic Review.
Evaluation of biomarker changes after administration of various neoadjuvant chemotherapies in breast cancer.
Guangchao Jin, Yu Han, +7 authors, Xingsong Tian.
Int J Clin Exp Pathol, 2015 Mar 11; 8(1). PMID: 25755795    Free PMC article.
EMT and dissemination precede pancreatic tumor formation.
Andrew D Rhim, Emily T Mirek, +9 authors, Ben Z Stanger.
Cell, 2012 Jan 24; 148(1-2). PMID: 22265420    Free PMC article.
Highly Cited.
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.
J Ferlay, E Steliarova-Foucher, +5 authors, F Bray.
Eur J Cancer, 2013 Mar 15; 49(6). PMID: 23485231
Highly Cited.
Relative and disease-free survival for breast cancer in relation to subtype: a population-based study.
Pamela Minicozzi, Francesca Bella, +10 authors, Milena Sant.
J Cancer Res Clin Oncol, 2013 Jul 31; 139(9). PMID: 23892409
Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer.
L Alexis Hoeferlin, Charles E Chalfant, Margaret A Park.
J Surg Sci, 2014 May 13; 1(1). PMID: 24818173    Free PMC article.
Analysis of Progress and Challenges of EGFR-Targeted Molecular Imaging in Cancer With a Focus on Affibody Molecules.
Weizhi Chen, Baozhong Shen, Xilin Sun.
Mol Imaging, 2019 Feb 26; 18. PMID: 30799684    Free PMC article.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, +3 authors, Ahmedin Jemal.
CA Cancer J Clin, 2018 Sep 13; 68(6). PMID: 30207593
Highly Cited.
Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging.
Eli C F Dijkers, Jos G W Kosterink, +6 authors, Marjolijn N Lub-de Hooge.
J Nucl Med, 2009 May 16; 50(6). PMID: 19443585
Highly Cited.
Metabolic flare: indicator of hormone responsiveness in advanced breast cancer.
J E Mortimer, F Dehdashti, +3 authors, M J Welch.
J Clin Oncol, 2001 Jun 02; 19(11). PMID: 11387350
Anti-MUC1 nano-aptamers for triple-negative breast cancer imaging by single-photon emission computed tomography in inducted animals: initial considerations.
Fagner Santos do Carmo, Eduardo Ricci-Junior, +4 authors, Ralph Santos-Oliveira.
Int J Nanomedicine, 2017 Jan 06; 12. PMID: 28053523    Free PMC article.
Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors.
Clément Morgat, Gaétan MacGrogan, +6 authors, Elif Hindié.
J Nucl Med, 2017 Mar 11; 58(9). PMID: 28280221
Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer.
Atsushi Yoshida, Naoki Hayashi, +3 authors, Hideko Yamauchi.
J Surg Oncol, 2017 Aug 03; 116(8). PMID: 28767137
International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?
Olivia Pagani, Elzbieta Senkus, +7 authors, ESO-MBC Task Force.
J Natl Cancer Inst, 2010 Mar 12; 102(7). PMID: 20220104    Free PMC article.
The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up.
Johanna Maffey-Steffan, Lorenza Scarpa, +8 authors, Irene Virgolini.
Eur J Nucl Med Mol Imaging, 2019 Nov 30; 47(3). PMID: 31776632    Free PMC article.
Detection, clinical relevance and specific biological properties of disseminating tumour cells.
Klaus Pantel, Ruud H Brakenhoff, Burkhard Brandt.
Nat Rev Cancer, 2008 Apr 12; 8(5). PMID: 18404148
Highly Cited. Review.
Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
Marleen Keyaerts, Catarina Xavier, +15 authors, Tony Lahoutte.
J Nucl Med, 2015 Oct 10; 57(1). PMID: 26449837
Highly Cited.
Biological response of cancer cells to radiation treatment.
Rajamanickam Baskar, Jiawen Dai, +2 authors, Kheng-Wei Yeoh.
Front Mol Biosci, 2014 Jan 01; 1. PMID: 25988165    Free PMC article.
Highly Cited. Review.
Theranostic Advances in Breast Cancer in Nuclear Medicine.
Nasim Vahidfar, Ayuob Aghanejad, +2 authors, Elisabeth Eppard.
Int J Mol Sci, 2021 May 01; 22(9). PMID: 33925632    Free PMC article.
Palmatine, a Bioactive Protoberberine Alkaloid Isolated from Berberis cretica, Inhibits the Growth of Human Estrogen Receptor-Positive Breast Cancer Cells and Acts Synergistically and Additively with Doxorubicin.
Aneta Grabarska, Paula Wróblewska-Łuczka, +5 authors, Andrzej Stepulak.
Molecules, 2021 Oct 24; 26(20). PMID: 34684834    Free PMC article.